Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant chemoradiotherapy plus cetuximab followed by TME surgery and postoperative FOLFOX4 plus cetuximab for metastatic rectal adenocarcinoma with initially resectable synchronous metastases
2006-003336-30Phase 2Active
- Sponsor
- Unicancer
- Start
- Mar 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, capecitabine, oxaliplatin, fluorouracil and folinic acid in rectal adenocarcinoma, sponsored by Unicancer. Started Mar 2007; status: active.
02
Drugs
cetuximabcapecitabineoxaliplatinfluorouracilfolinic acid
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on 2006-003336-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003336-30.